These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 18203315

  • 1. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy.
    Briot K, Roux C, Gossec L, Charni N, Kolta S, Dougados M, Garnero P.
    J Rheumatol; 2008 Feb; 35(2):310-4. PubMed ID: 18203315
    [Abstract] [Full Text] [Related]

  • 2. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 4. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD.
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [Abstract] [Full Text] [Related]

  • 5. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment.
    Briot K, Garnero P, Le Henanff A, Dougados M, Roux C.
    Ann Rheum Dis; 2005 Aug; 64(8):1137-40. PubMed ID: 15642695
    [Abstract] [Full Text] [Related]

  • 6. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.
    Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD.
    Arthritis Rheum; 2002 Oct; 46(10):2613-24. PubMed ID: 12384919
    [Abstract] [Full Text] [Related]

  • 7. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K, Gossec L, Kolta S, Dougados M, Roux C.
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [Abstract] [Full Text] [Related]

  • 8. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N, Juillet F, Garnero P.
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [Abstract] [Full Text] [Related]

  • 9. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response.
    Kim TH, Stone M, Payne U, Zhang X, Ionescu M, Lobanok T, King L, Poole AR, Inman RD.
    Arthritis Rheum; 2005 Mar; 52(3):885-91. PubMed ID: 15751093
    [Abstract] [Full Text] [Related]

  • 10. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies.
    Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F, Veys EM, Baeten D.
    Arthritis Rheum; 2005 Dec; 52(12):3898-909. PubMed ID: 16329106
    [Abstract] [Full Text] [Related]

  • 11. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers.
    Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lobanok T, Ionescu M, Poole AR, Esdaile JM.
    J Rheumatol; 2005 May; 32(5):896-902. PubMed ID: 15868627
    [Abstract] [Full Text] [Related]

  • 12. Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456].
    Forsblad d'Elia H, Christgau S, Mattsson LA, Saxne T, Ohlsson C, Nordborg E, Carlsten H.
    Arthritis Res Ther; 2004 May; 6(5):R457-68. PubMed ID: 15380045
    [Abstract] [Full Text] [Related]

  • 13. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial.
    Pullerits R, d'Elia HF, Tarkowski A, Carlsten H.
    Rheumatology (Oxford); 2009 Jul; 48(7):785-90. PubMed ID: 19416946
    [Abstract] [Full Text] [Related]

  • 14. Effects of continuous oral administration of phenylbutazone on biomarkers of cartilage and bone metabolism in horses.
    Fradette ME, Céleste C, Richard H, Beauchamp G, Laverty S.
    Am J Vet Res; 2007 Feb; 68(2):128-33. PubMed ID: 17269876
    [Abstract] [Full Text] [Related]

  • 15. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation.
    Oestergaard S, Sondergaard BC, Hoegh-Andersen P, Henriksen K, Qvist P, Christiansen C, Tankó LB, Karsdal MA.
    Arthritis Rheum; 2006 Aug; 54(8):2441-51. PubMed ID: 16871544
    [Abstract] [Full Text] [Related]

  • 16. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.
    Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, Haas-Smith SA, Ritchlin CT.
    Ann Rheum Dis; 2008 Mar; 67(3):296-301. PubMed ID: 17967829
    [Abstract] [Full Text] [Related]

  • 17. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis.
    Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB.
    Arthritis Rheum; 2006 Aug; 54(8):2496-504. PubMed ID: 16868970
    [Abstract] [Full Text] [Related]

  • 18. [Clinical significance of serum cartilage biomarkers in the treatment of rheumatoid arthritis with biological therapy].
    Niki Y, Takeuchi T.
    Clin Calcium; 2012 Feb; 22(2):205-12. PubMed ID: 22298074
    [Abstract] [Full Text] [Related]

  • 19. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy.
    Jansen NW, Roosendaal G, Lundin B, Heijnen L, Mauser-Bunschoten E, Bijlsma JW, Theobald M, Lafeber FP.
    Arthritis Rheum; 2009 Jan; 60(1):290-8. PubMed ID: 19116938
    [Abstract] [Full Text] [Related]

  • 20. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
    Hakala M, Risteli J, Aman S, Kautiainen H, Korpela M, Hannonen P, Leirisalo-Repo M, Laasonen L, Paimela L, Möttönen T, Fin-Raco Trial Group.
    Scand J Rheumatol; 2008 Jan; 37(2):90-3. PubMed ID: 18415764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.